|Publication Date||March 2010|
Print £1550 $2430
|Add to Basket|
PDF £1495 $2345
|Add to Basket|
PDF £7510 $11775
|Add to Basket|
Although a number of major companies have significant biological capabilities, few apart from Novartis have yet clearly developed strategies to compete in the biosimilars market
Since Sandoz pioneered the development of biosimilar drugs in 2001 there has been a steady breakdown of regulatory resistance. However, there are considerable entry barriers hindering companies that wish to enter this field of therapeutics.
Biosimilars – A Growing Market is a unique report from URCH Publishing that provides the reader with a comprehensive review of the current and future market for biosimilar products,
Some key findings from the report:
Chapter 1 focuses on the development history of biosimilars and provides an overview of the environment.
Chapter 2 considers the progress towards the development of approval pathways for this class of agents in the US and Japan, together with the current European framework. It also briefly addresses the position in other markets.
Chapter 3 discusses the substantial hurdles that must be surmounted by those companies that wish to develop and market biosimilars. And these are additional to the regulatory hurdles that are discussed in chapter 2.
Chapter 4 examines the blossoming European market for biosimilars. The regulatory barriers to their approval in both Japan and the US have ensured that few biosimilars are yet available in those markets.
Chapter 5 highlights the key factors that suggest that the successful development and marketing of a biosimilar product is commercially advantageous. It also covers, subject to the availability of suitable enabling legislation in the US and Japan, which biosimilars products might enter the market.
Chapter 6 analyses the impact of biosimilars upon specialist, generic and market pharmaceutical companies. A number of key companies are profiled.
Chapter 7 looks to the future and considers which factors will impact the market for biosimilars. The high cost of these products and the increasing pressure that they place on healthcare budgets is likely to prove a major driver in the adoption and uptake of biosimilars, even in the US market.
The report concludes by assessing the market outlook over the period 2010–20, which is forced to rely on certain key assumptions owing to current uncertainties as to when biosimilar products will become available in the US.
Companies mentioned in the report include:
3SBio, Abbott, Amgen, AnGes, AstraZeneca, Barr Pharmaceuticals, Bayer Schering, Bharat Biotech, Bioceuticals, Biocon, Biogen Idec, Bioton, Cambridge Antibody Technology, Celgene, Chugai, Daiichi Sankyo, Dainippon Sumitomu, r Reddy’s, Dragon Pharmaceuticals, Eisai, Eli Lilly, Genentech, Genzyme, Hospira, ImClone, Intas Pharmaceuticals,Johnson & Johnson, Kyowa Hakko Kirin, LG Life Sciences, Lonza AG, MedImmune, Merck, Merck Serono, Mitsubishi Tanabe, Mylan, Neulasta, Novartis (Sandoz), Panacea Biotec, Pfizer, PharmAthene, Ranbaxy, Raptiva, Ratiopharm, Roche, Roche/Genentech, Schering-Plough, Shantha, Biotechnics, Stada, Takeda, Teva, Toray, UCB, Wockhardt, Wyeth, Xoma
Drugs mentioned in the report include:
Abseamed, Actemra, Aldurazyme, Aranesp, Avastin, Avonex, Betaseron, Binocrit, Cerezyme, Cimzia, Enbrel, Epoetin, Epogen, ESPO, Feron, Glaritus, Granocyte, Herceptin, Humira, IntronA, Lucentis, Macrogen, Mircera, Myozyme, Naglazyme, NeoRecormon, Nesp, Neugranin, Neulasta, Neupogen, NuGraf, Omnitrope, Pegasys, PegIntron, Procrit, Ratiograstim, Rebif, Reditux, Remicade, Replagal, Revlimid, Rituxan, Roferon-A, Synagis
List of Figures
Figure 1.1 2008 sales and year of launch of leading biological products
Figure 2.1 Market exclusivity for reference products and timing of biosimilar Marketing Authorisation Applications (MAAs)
Figure 2.2 Centralised procedure for MAAs
Figure 2.3 Number of new biologics approved in Japan, 2001-08
Figure 4.1 Biosimilar MAAs submitted for initial evaluation
Figure 5.1 Worldwide sales of biological products by patent expiration year and 2008 revenues of those products
Figure 5.2 Approval of new biological agents in Japan, 2001-08
List of Tables
Table 2.1 Quantity of data required for MAAs for generic and biosimilar products (as number of lever-arch files)
Table 2.2 Data requirements for MAAs for generic and biosimilar products
Table 5.1 Leading biotechnology therapeutics (excluding insulin derivatives and vaccines) showing reported global sales for 2007 and 2008
Table 5.2 Top 11 classes of biotechnology therapeutics (excluding vaccines) showing reported global sales for 2007 and 2008
Table 5.3 Expiration dates of market exclusivity of key biological products in the major European countries
Table 5.4 Expiration dates of market exclusivity of key biological products in the US
Table 5.5 Amgen's key epoetin patents in the US
Table 5.6 Approval dates of selected biological products in Japan
Table 7.1 Timeline of anticipated key events, 2010-17 (those in the US and Japan assume that legislation is enacted as discussed)